MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2025 International Congress

    ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy

    D. Stamler, C. Wong, P. Trujillo, M. Bradbury, C. Lucas, K. Kmiecik, D. Claassen (Newark, USA)

    Objective: Evaluate the efficacy and safety of ATH434 treatment in individuals with MSA Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder without…
  • 2025 International Congress

    A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease

    A. Matta, X. Valencia, K. Pike, L. Warner, O. Spiegelstein, M. Bigal (Waltham, USA)

    Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…
  • 2025 International Congress

    Bidirectional Relationships Between Frailty and DNAm Age Acceleration and its Mediation Effects on Physical Disability and Mortality

    C. Han, J. Chhetri, P. Chan (Beijing, China)

    Objective: This study aims to investigate the bidirectional associations between frailty and DNA methylation (DNAm) age acceleration (AgeAccel), and further test whether epigenetic aging mediates…
  • 2025 International Congress

    PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment

    T. Nikolcheva, G. Pagano, J. Anzures-Cabrera, T. Simuni, K. Marek, N. Pavese, K. Seppi, F. Stocchi, R. Postuma, N. Pross, A. Monnet, G. Respondek, L. Rutten-Jacobs, V. Schlegel, L. Boak, G. Kerchner, P. Brundin, H. Svoboda, A. Bonni (Basel, Switzerland)

    Objective: To evaluate the effect of prasinezumab on slowing down disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab…
  • 2025 International Congress

    Neuroprotective Role of Diosgenin-Loaded Lipid Nanoparticles for Parkinson’s Disease: Pharmacokinetic and Pharmacodynamic Insights

    R. Rajput, S. Verma (Agra, India)

    Objective: To develop, optimize, and evaluate diosgenin-loaded solid lipid nanoparticles (DG-SLNs) and nanostructured lipid carriers (DG-NLCs) incorporated into hydrogel formulations (DG-SLN-C and DG-NLC-C) for improved…
  • 2025 International Congress

    Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease

    N. Vijiaratnam, C. Girges, J. Dickson, C. Caroll, M. Silverdale, M. Hu, G. Duncan, K. Chaudhuri, S. Gandhi, D. Athauda, Y. Li, N. Greig, K. Chowdhury, T. Foltynie (London, United Kingdom)

    Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…
  • 2025 International Congress

    Therapeutic Efficacy of Human Dental Pulp Stem Cells-Derived Exosome-Encased Phloroglucinol In MPTP-Induced Chronic Parkinsonian Rat model: Potential for Disease Modification

    I. Datta, K. Mondal, R. Ghanty, G. Wagmare, A. Mahadevan, R. Santhoshkumar, N. Bn (Bengaluru, India)

    Objective: This study aimed to evaluate the therapeutic efficacy of intranasally administered exosome-encased phloroglucinol (Exo-Phl) in a MPTP rat model of PD. Background: Dopaminergic (DA)…
  • 2025 International Congress

    Cognitive and Motor Wobbling in Isolated RBD: A Multicentric Study by the International RBD Study Group (IRBDSG)

    A. Stefani, S. Joza, D. Arnaldi, L. Baldelli, G. Benbir, B. Boeve, V. de Cock, L. Churchill, B. Högl, M. Hu, B. Huang, R. Kim, K. Kufer, J-Y. Lee, C. Liguori, B. Mollenhauer, L. Muntean, N. Li, B. Orso, M. Patyjewicz, R. Postuma, F. Provini, S. Lewis, C. Simonet, M. Sommerauer, A. Videnovic, Y. Wing, C. Trenkwalder (Innsbruck, Austria)

    Objective: To define and characterize clinically fluctuating transition phases from isolated RBD (iRBD) to overt alpha-synucleinopathy. Background: Patients with iRBD often develop motor and non-motor…
  • 2024 International Congress

    Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.

    F. Reis Rodrigues, E. Pasqualotto, G. Ribeiro, J. M. Couto, E. Bayram, M. Ushe, D. Di Luca (Vicosa, Brazil)

    Objective: To perform a systematic review and meta-analysis on recruitment of people with Parkinson’s disease (PwP, PD) from different ethnic and racial groups in disease-modifying…
  • 2024 International Congress

    Chronic Sleep Fragmentation Accelerates the Onset of Prodromal Symptoms and Pathology in Parkinson’s Disease Model Mice

    M. Miyazaki, H. Yagihara, H. Fujita, H. Yamakado, K. Wada, E. Minakawa (Kodaira, Japan)

    Objective: To investigate whether chronic sleep fragmentation accelerates the onset of prodromal symptoms and pathology of Parkinson’s disease (PD) in mice. Background: The prodromal phase…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley